Compare DWSN & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DWSN | IFRX |
|---|---|---|
| Founded | 1952 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4M | 67.0M |
| IPO Year | N/A | 2017 |
| Metric | DWSN | IFRX |
|---|---|---|
| Price | $2.12 | $0.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 65.5K | ★ 609.3K |
| Earning Date | 11-12-2025 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $64,312,000.00 | $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,054.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.08 | $0.71 |
| 52 Week High | $5.54 | $2.77 |
| Indicator | DWSN | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.34 | 36.10 |
| Support Level | $2.00 | $0.88 |
| Resistance Level | $2.34 | $1.01 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 50.31 | 8.87 |
Dawson Geophysical Co is a provider of onshore seismic data acquisition services with operations throughout the continental United States and Canada. The company acquires and processes 2 D, 3 D, and multi-component seismic data for clients, ranging from oil and gas companies to independent oil and gas operators for use in the onshore drilling and production of oil and natural gas as well as provides multi-client data libraries. It operates through a single segment being Contract seismic data acquisition and processing services. In addition, the company provides multi-component seismic data surveys which involve the recording of alternative seismic waves. Geographically, it generates maximum revenue from the United States.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.